• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Asthma research and practice. >Asthma in the elderly: a double-blind, placebo-controlled study of the effect of montelukast
【24h】

Asthma in the elderly: a double-blind, placebo-controlled study of the effect of montelukast

机译：老年人哮喘：孟鲁司特效果的双盲，安慰剂对照研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BackgroundLittle is known about asthma in the elderly as most studies of this condition have not included this patient group. It is unclear whether leukotriene antagonists benefit older asthmatics. We studied the effect of adding montelukast to the asthma treatment of elderly subjects. MethodsTwenty-five subjects 65?years old and older with asthma were evaluated at week 0, 1, 5, 9, 13, and 17. Each subject received montelukast 10?mg and placebo each for 8?weeks in a cross-over design. ResultsMontelukast for 4 or 8?weeks did not significantly affect ACT, daily symptom scores, number of puffs of albuterol, spirometric values, peripheral blood eosinophils, or serum IgE vs. baseline or placebo. Similar results were obtained when analyzing subgroups of patients with lower ACT, lower FEV1, and higher eosinophils. ConclusionsIn this study of elderly asthmatics, montelukast had no effect on asthma symptoms, number of puffs of albuterol, spirometric values, peripheral blood eosinophils or serum IgE. These results will require confirmation in larger patient cohorts and in patients with uncontrolled asthmatic symptoms.
机译：背景：关于老年人哮喘的知识鲜为人知，因为大多数对此病的研究并未将其纳入该患者组。尚不清楚白三烯拮抗剂是否有益于老年哮喘患者。我们研究了将孟鲁司特添加到老年患者的哮喘治疗中的效果。方法在第0、1、5、9、13和17周对65名65岁及65岁以上的哮喘患者进行了评估，采用交叉设计，每名受试者分别接受10 mg孟鲁司特和安慰剂治疗8周。结果孟鲁司特治疗4或8周没有显着影响ACT，每日症状评分，沙丁胺醇抽吸量，肺功能测定值，外周血嗜酸性粒细胞或血清IgE相对于基线或安慰剂的影响。分析具有较低ACT，较低FEV1和较高嗜酸性粒细胞的患者亚组时，获得了相似的结果。结论在这项对老年哮喘患者的研究中，孟鲁司特对哮喘症状，扑喘的沙丁胺醇数量，肺活量测定值，外周血嗜酸性粒细胞或血清IgE没有影响。这些结果将需要在较大的患者队列和哮喘症状未得到控制的患者中得到证实。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号